Abstract
Various human tumors preferentially metastasize by lymphatic route and lymphovascular invasion predicts lymph node metastasis. In this review article, we will summarize recent literature data concerning lymphangiogenesis, focusing on tumor lymphangiogenesis. In detail, we try to answer some important questions related to: a) The specificity of lymphatic endothelial cell markers; b) The differential characteristics of lymphatic vessels in tumors; c) The interplay between different lymphangiogenic factors; d) The role of pre-existing and newly-formed lymphatic vessels in tumors and their proliferative potential; e) The role of lymphatic vessels in tumor metastases; e) The prognostic significance of lymphatic microvascular density in tumors; f) The inhibition of lymphangiogenesis in tumors.
Keywords: Lymphangiogenesis, lymphatic endothelial cell, lymphatic microvascular density, metastases, tumor progression, vascular endothelial growth factor
Current Medicinal Chemistry
Title: Targeting Tumor Lymphangiogenesis: An Update
Volume: 17 Issue: 8
Author(s): M. Raica and D. Ribatti
Affiliation:
Keywords: Lymphangiogenesis, lymphatic endothelial cell, lymphatic microvascular density, metastases, tumor progression, vascular endothelial growth factor
Abstract: Various human tumors preferentially metastasize by lymphatic route and lymphovascular invasion predicts lymph node metastasis. In this review article, we will summarize recent literature data concerning lymphangiogenesis, focusing on tumor lymphangiogenesis. In detail, we try to answer some important questions related to: a) The specificity of lymphatic endothelial cell markers; b) The differential characteristics of lymphatic vessels in tumors; c) The interplay between different lymphangiogenic factors; d) The role of pre-existing and newly-formed lymphatic vessels in tumors and their proliferative potential; e) The role of lymphatic vessels in tumor metastases; e) The prognostic significance of lymphatic microvascular density in tumors; f) The inhibition of lymphangiogenesis in tumors.
Export Options
About this article
Cite this article as:
Raica M. and Ribatti D., Targeting Tumor Lymphangiogenesis: An Update, Current Medicinal Chemistry 2010; 17 (8) . https://dx.doi.org/10.2174/092986710790514471
DOI https://dx.doi.org/10.2174/092986710790514471 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Meta-Analysis of Anticancer Drug Structures - Significance of Their Polar Allylic Moieties
Anti-Cancer Agents in Medicinal Chemistry Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design Recent Developments in Tumor Angiogenesis
Current Pharmaceutical Biotechnology Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design The Use of PET for Radiotherapy
Current Medical Imaging The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer
Current Drug Targets Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design